Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical begins landmark Alzheimer’s disease clinical trial

The largest Alzheimer’s study ever conducted by an Australian company.
Actinogen Medical begins landmark Alzheimer’s disease clinical trial
Xanamem represents a potential breakthrough in treating Alzheimer’s

Actinogen Medical (ASX:ACW) has reached a major milestone with the first patient treated in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease.

Xanamem has been specifically designed to block the production of excess cortisol in the brain.

Cortisol is a hormone produced by the body in times of stress and there is a growing body of research that shows a strong association between excess cortisol and Alzheimer’s disease. 

This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University and Actinogen.

The first patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia.

Other trial sites in Australia, the U.S. and the UK will soon start recruiting patients, with the final patient expected by Q4 2018, and top-line results for the trial expected in Q1 2019.

Xanamem represents a potential breakthrough in treating Alzheimer’s disease at a time when several high-profile drug trials based on more traditional approaches have failed.

XanADu, the largest global Alzheimer’s dementia study ever conducted by an Australian biotech company, will enrol 174 patients at 20 research sites across Australia, the UK and the U.S.

In the U.S. alone, the cost of managing Alzheimer’s disease is estimated to be US$250 billion, and is set to increase to US$2 trillion by 2050, outstripping the treatment costs of all other diseases.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
blood cells
October 04 2017
The two parts of the business - the commercial arm and research function - appear to be firing on all cylinders

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use